---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-038577"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:06:15.963934+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update

## Summary
- Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.
- R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.
- Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.
- Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.
- New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024.

## SEC filing metadata
- accession: 0001213900-23-038577
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/0001213900-23-038577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/ea178401-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-038577
- JSON: https://secwatch.observer/filing/0001213900-23-038577.json
- Plain text: https://secwatch.observer/filing/0001213900-23-038577.txt

## Key facts
- Earnings Releases
  RELMADA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share, EPS $0.87 per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - Net income: Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share
  - EPS: $0.87 per basic and diluted share
  - Result: preliminary results
  source text: Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/0001213900-23-038577-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.